Home   >  
Neuro Signaling Pathway
Beta secretase

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products






Raw Materials

Beta secretase

Chemical Structure Cat. No. Product Name CAS No.
AZD3839 Chemical Structure
BCP13212 AZD3839 1227163-56-5
AZD3839, with the potential to treat Alzheimer’s disease, was reported as a selective BACE1 inhibitor (IC50=4.8μM) for which concentration-dependent lowering of Ab peptides in cellular systems and three pre-clinical species were demonstrated.
Umibecestat Chemical Structure
BCP30325 Umibecestat 1387560-01-1
Umibecestat, also known as CNP-520, is a beta-secretase inhibitor and is a drug candidate for prevention trials in Alzheimer's disease.
RG7129 Chemical Structure
BCP23733 RG7129 1310347-50-2
RG7129 is a potent BACE inhibitor with IC50 of 30 nM for BACE1, equally potent against BACE2 (IC50=40 nM).
Sophoflavescenol Chemical Structure
BCP24815 Sophoflavescenol 216450-65-6
Sophoflavescenol is a prenylated flavonol, which shows great inhibitory activity with IC50 of 0.013 μM against Phosphodiesterase 5 (PDE5), and also inhibits RLAR, HRAR, AGE, BACE1, AChE and BChE with IC50s of 0.30 µM, 0.17 µM, 17.89 µg/mL, 10.98 µM, 8.37 µM and 8.21 µM, respectively.
AZD3839 Chemical Structure
BCP23892 AZD3839 1227163-84-9
AZD3839 is a potent and selective BACE1 inhibitor with IC50 of 23.6 uM, about 14-fold selectivity over BACE2, also a β-secretase enzyme inhibitor.
Eslicarbazepine acetate Chemical Structure
BCP07117 Eslicarbazepine acetate 236395-14-5
Voltage-gated sodium channel blocker; significantly blocks excitatory amino acid (glutamate and aspartate) release.
LX-2343 Chemical Structure
BCP28952 LX-2343 333745-53-2
LX2343 is a BACE1 enzyme inhibitor with an IC50 value of 11.43±0.36 μM. LX2343 acts as a non-ATP competitive PI3K inhibitor with an IC50 of 15.99±3.23 μM. LX2343 stimulates autophagy in its promotion of Aβ clearance.
Lanabecestat Chemical Structure
BCP16986 Lanabecestat 1383982-64-6
AZD3293 is a potent and selective orally active, brain-permeable BACE1 inhibitor,currently in development as a potential treatment for early Alzheimer’s disease.
LY2886721 Chemical Structure
BCP02507 LY2886721 1262036-50-9
LY2886721 is a novel potent agent that is used to treat Alzheimer’s Disease in preclinical experiments.
Verubecestat Chemical Structure
BCP15722 Verubecestat 1286770-55-5
MK-8931 is a BACE1 inhibitor. MK-8931 binds significantly to β-secretase.
12下一页共 13 条记录 1 / 2 页